Viral Persistence After Liver Transplantation for Hepatitis B Virus: A Cross-Sectional Study

Abstract

Our observations imply that the selection of resistant virus may be essential, but is not sufficient to cause overt failure of prophylaxis with development of clinical disease. It seems likely that the patients' immune response contributes, at least partially, to the long-term control of infection in these patients.

Prevention of Post-transplant HBV

“…Post-LT a : Viral suppression is the goal for all patients before liver transplantation using Entecavir or There was no significant difference in the proportion of HBsAg positivity between the LAM, ETV, or combination therapy groups (20,17, and 21 %). These studies highlight several important issues to consider regarding HBV prophylaxis using HBIG-free regimens.…”

Different effect of HBV vaccine after liver transplantation between chronic HBV carriers and non-HBV patients who received HBcAb-positive grafts

“…HBsAb [100 IU/l without HBIg administration for more than 3 months was judged to indicate success of this vaccine protocol according to the previous reports for HBV prophylaxis [11,26,27] and vaccine effect [28,29]. If this level could be attained, lamivudine treatment could be stopped.…”

Controversies Regarding the Hepatitis B Immune Globulin Prophylaxis (HBIG) for Liver Transplantation Recipients

“…Although the sample size of the patients-studied was low in compare with Lam-receiving patients, the reported recurrence after prophylaxis with ADV was 0% [44,87,99] . Among new NAs, entecavir, telbivudine, tenofovir and emtricitabine have been used with 0% recurrence rate (Table 2) [22, 46,56,93,95,[100][101][102][103][104][105] .…”

“…Further, comparison of trails that used a combination of antivirals compared with a combination of HBIg plus either NA alone showed that both regimens provides equivalent protection against recurrent HBV infection after LTx with fewer side effects and lower cost [32,88] . Furthermore, treatment with adefovir plus lamivudine before LTx and the addition of HBIg after LTx has shown to prevent graft reinfection [7,87,94,99] .…”

“…Angus/2008 [32] Avolio/2008 [106] Angus/2000 [51] Anselmo/2002 [33] Anderson/2007 [107] Alonso/2003 [108] Brock/2011 [109] Buti/2003 [110] Ben-Ari/2004 [111] Chun/2010 [112] Dadson/2000 [113] Dehghani/2013 [114] Dickson/2006 [59] Dumortier/2003 [115] Degertekin/2010 [116] Di Paolo/2004 [117] Faust/2003 [118] Freshwater/2008 [99] Fabrega/2003 [119] Feretti/2004 [120] Filipponi/2010 [121] Gane/2013 [55] Han/2000 [35] Han/2003 [122] Honaker/2002 [123] Iacob/2008 [124] Jiang/2010 [125] Jain/2005 [126] Jiao/2007 [127] Karademir/2006 [128] Kwon/2006 [129] Lee/2000 [130] Lee/2004 [131] Lu/2004 [85] Lu/2008 [39] Loss/2003 [132]…”